Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.57 |
| ▸ | AXL | P30530 | 1/20 | 0.52 |
| ▸ | CSF1R | P07333 | 8/20 | 0.49 |
| ▸ | BRAF | P15056 | 7/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.49 |
| ▸ | MET | P08581 | 4/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.49 |
| ▸ | FLT3 | P36888 | 3/20 | 0.49 |
| ▸ | KIT | P10721 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL572704 | 0.92 | KDR (0.57) | KDRAXLCSF1RBRAFPDGFRA | |
| SCHEMBL574507 | 0.90 | BRAF (0.61) | KDRAXLBRAF | |
| SCHEMBL572509 | 0.88 | KDR (0.64) | KDRAXLCSF1RBRAFPDGFRA | |
| SCHEMBL573441 | 0.88 | KDR (0.58) | KDRAXLCSF1RBRAFPDGFRA | |
| SCHEMBL573931 | 0.86 | KDR (0.54) | KDRAXLCSF1RBRAFPDGFRA | |
| SCHEMBL573247 | 0.86 | KDR (0.63) | KDRAXLCSF1RBRAFPDGFRA | |
| SCHEMBL574393 | 0.84 | KDR (0.57) | KDRAXLCSF1RBRAFPDGFRA | |
| SCHEMBL574030 | 0.84 | MAPK14 (0.60) | KDRAXLCSF1RBRAFPDGFRA | |
| SCHEMBL3665924 | 0.82 | AXL (0.61) | KDRAXLCSF1RPDGFRAMET | |
| SCHEMBL573559 | 0.82 | KDR (0.56) | KDRAXLCSF1RBRAFPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143293-B2 | disease caused by c-Abl kinase, c-Kit kinase, oncogenic forms, aberrant fusion proteins and polymorphs; 1-(3-t-butylisoxazol-5-yl)-3-(2-fluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)urea | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-03-27 | — | — | US | claimed |
| US-8143293-B2 | disease caused by c-Abl kinase, c-Kit kinase, oncogenic forms, aberrant fusion proteins and polymorphs; 1-(3-t-butylisoxazol-5-yl)-3-(2-fluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)urea | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-03-27 | — | — | US | disclosed |
| WO-2012019015-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | DECIPHERA PHARMACEUTICALS, LLC | 2011-08-04 | — | — | US | disclosed |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | MCL1, NRAS, ABL1 | KDR 2434/4885AXL 2089/4885CSF1R 1244/4885 |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, PRKACA, BRAF | KDR 239/4885AXL 338/4885CSF1R 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.